Compare AENT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AENT | CRDF |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.7M | 142.1M |
| IPO Year | N/A | N/A |
| Metric | AENT | CRDF |
|---|---|---|
| Price | $7.73 | $2.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $10.00 | ★ $10.63 |
| AVG Volume (30 Days) | 54.7K | ★ 917.3K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.70 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $1,088,441,000.00 | $501,000.00 |
| Revenue This Year | $7.29 | N/A |
| Revenue Next Year | $1.84 | N/A |
| P/E Ratio | $18.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.21 | $1.90 |
| 52 Week High | $11.57 | $5.64 |
| Indicator | AENT | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 59.51 | 64.20 |
| Support Level | $7.07 | $2.32 |
| Resistance Level | $8.45 | $2.59 |
| Average True Range (ATR) | 0.55 | 0.14 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 64.02 | 87.61 |
Alliance Entertainment Holding Corp is a distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world. The company has two divisions: Alliance Home Entertainment, which offers full-service support across production, marketing, and retail execution. and Alliance Authentic, which focuses on licensed collectibles and branded merchandise, including partnerships with Handmade by Robots, Master Replicas, and Weta Workshop.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.